| 2025-11-25 |
股东大会：
将于2025-12-30召开股东大会
会议内容 ▼▲
- 1.To approve the re-election of Dr, Ehud Geller to the Board of Directors as a Class I director, so that following such re-election, his term shall expire in accordance with his class.
2.To approve, subject to and conditional upon the approval of the Registrar of Companies of Israel, the name of the Company to be changed from “Painreform Ltd.” to “PRF Ltd.” and to amend the Company’s amended and restated articles of association (the “Articles of Association”) accordingly.
3.To approve a grant of options to Asaf Shavit, a member of the Board of Directors.
4.To approve an increase of the Company’s authorized share capital by 50,000,000 shares, such that following the increase, the authorized share capital will consist of a total of 60,000,000 ordinary shares, with no nominal value each, and to amend the Company’s Articles of Association accordingly.
5.To approve a reverse split of the Company ordinary shares, with no nominal value each, at a ratio of 1 share for 5 shares, so that each five (5) ordinary shares of the Company, with no nominal value each shall be recapitalized into one (1) ordinary share of the Company, with no nominal value, and to amend the Company’s Articles of Association.
6.To approve the re-appointment of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited (the “Auditors”), as the Company’s independent registered public accounting firm for the year ending December 31, 2025, and to authorize the Board of Directors, upon the recommendation of the Company’s audit committee, to determine the Auditors’ remuneration to be fixed in accordance with the volume and nature of their services to the Company for such fiscal year.
7.To review and discuss our financial statements for the year ended December 31, 2024, and to transact such other business as may properly come before the Meeting.
|
| 2025-11-25 |
详情>>
股本变动：
变动后总股本391.53万股
|
| 2025-10-01 |
详情>>
业绩披露：
2025年中报每股收益-1.09美元,归母净利润-231.6万美元,同比去年增长81.93%
|
| 2025-08-19 |
复牌提示：
2025-08-19 09:41:33 停牌，复牌日期 2025-08-19 09:46:33
|
| 2025-04-07 |
详情>>
业绩披露：
2024年年报每股收益-32.16美元,归母净利润-1458.8万美元,同比去年增长-56.12%
|
| 2025-02-27 |
股东大会：
将于2025-04-03召开股东大会
会议内容 ▼▲
- 1.To approve an increase of the Company’s authorized share capital by 7,500,000 shares, such that following the increase, the authorized share capital shall be divided into 10,000,000 ordinary shares, no nominal value each, and to amend the Company’s articles of association accordingly;
2.To approve the compensation terms of Dr. Ehud Geller in his capacity as the Interim Chief Executive Officer of the Company;
3.To approve a grant of options to Mr. Efi Cohen-Arazi, a member of the Board of Directors, and to Prof. Eli Hazum, the Chief Technology Officer of the Company and a member of the Board of Directors.
|
| 2024-11-08 |
详情>>
拆分方案：
每4.0000合并分成1.0000股
|
| 2024-11-04 |
股东大会：
将于2024-11-04召开股东大会
会议内容 ▼▲
- 1.To approve a reverse split of the Company ordinary shares, so that each four (4) ordinary shares of the Company with no nominal value, shall be recapitalized into one (1) ordinary share of the Company at a ratio of 1 share for 4 shares, and to amend the Company Articles of Association accordingly.
2.To approve a grant of options to Dr. Ehud Geller the Interim Chief Executive Officer, and to Prof. Eli Hazum, the Company Chief Technology Officer, who are both members of the Board of Directors.
|
| 2024-11-04 |
股东大会：
将于2024-11-11召开股东大会
会议内容 ▼▲
- 1.To approve a reverse split of the Company ordinary shares, so that each four (4) ordinary shares of the Company with no nominal value, shall be recapitalized into one (1) ordinary share of the Company at a ratio of 1 share for 4 shares, and to amend the Company Articles of Association accordingly.
2.To approve a grant of options to Dr. Ehud Geller the Interim Chief Executive Officer, and to Prof. Eli Hazum, the Company Chief Technology Officer, who are both members of the Board of Directors.
|
| 2024-09-09 |
详情>>
拆分方案：
每6.0000合并分成1.0000股
|
| 2024-08-26 |
股东大会：
将于2024-09-30召开股东大会
会议内容 ▼▲
- 1.To approve, upon the recommendation of the Company’s audit committee and of the Board of Directors, the re-election of Mr. Augustine Lawlor to hold office as an external director of the Company for a second period of three years, effective from September 1, 2023.
2.To approve, upon the recommendation of the Company’s audit committee and of the Board of Directors, the re-election of Dr. Ellen S. Baron to hold office as an external director of the Company for a second period of three years, effective from September 1, 2023.
3.To approve the grant of options to each of the other Company’s directors, excluding Dr. Ehud Geller and the external directors (a separate vote for each director will be taken).
4.To approve the grant of options to Dr. Ehud Geller, our Chairman of the Board and Interim Chief Executive Officer.
5.To approve the grant of options to Augustine Lawlor and to Dr. Ellen S. Baron, each an external director of the Company, subject to the approval of Proposal 1 and Proposal 2 (a separate vote for each director will be taken).
6.To approve the re-appointment of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited (the “Auditors”), as the Company’s independent registered public accounting firm for the year ending December 31, 2024, and to authorize the Board of Directors, upon the recommendation of the Company’s audit committee, to determine the Auditors’ remuneration to be fixed in accordance with the volume and nature of their services to the Company for such fiscal year.
7.To review and discuss our financial statements for the year ended December 31, 2023, and to transact such other business as may properly come before the meeting.
|
| 2024-08-15 |
详情>>
业绩披露：
2024年中报每股收益-3.12美元,归母净利润-1281.8万美元,同比去年增长-185.54%
|
| 2024-07-09 |
股东大会：
将于2024-08-13召开股东大会
会议内容 ▼▲
- 1.To approve certain amendments to the Company’s Amended and Restated Articles of Association relating to the appointment of directors of the Company, including to classify the Board of Directors (the “Board of Directors”) (other than the external directors) into three classes with staggered three-year terms.
2.To approve the re-election of Dr. Ehud Geller, Prof. Eli Hazum, and Efi Cohen-Arazi to the Board of Directors of the Company, each until the next annual general meeting of shareholders, or each to serve for staggered terms ending in accordance with his class, subject to the approval of Proposal 1 (a separate vote for each director will be taken).
3.To increase the Company’s authorized share capital by 40,000,000 shares, such that following the increase, the authorized share capital shall be divided into 60,000,000 ordinary shares, nominal value NIS 0.3 each, and to amend the Company’s articles of association accordingly.
4.To cancel the nominal value of the Company’s ordinary shares such that, subject to the approval of Proposal 3, the Company’s authorized share capital will be divided into 60,000,000 ordinary shares with no nominal value, and to amend the Company’s articles of association accordingly.
5.To approve a reverse split of the Company ordinary shares, so that each six (6) ordinary shares of the Company with no nominal value, subject to the approval of Proposal 4, shall be recapitalized into one (1) ordinary share of the Company at a ratio of 1 share for 6 shares, and to amend the Company Articles of Association accordingly.
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-2.72美元,归母净利润-550.6万美元,同比去年增长-138.56%
|
| 2024-03-07 |
股东大会：
将于2024-04-08召开股东大会
会议内容 ▼▲
- 1.To increase the Company’s authorized share capital by 15,000,000 shares, such that following the increase, the authorized share capital shall equal NIS 6,000,000 divided into 20,000,000 ordinary shares, par value NIS 0.3 each, and to amend the Company’s Articles of Association accordingly.
2.To ratify an amendment to the Company’s compensation policy as proposed within the Board of Directors resolution dated as of November 27, 2023 with respect to the adoption of a new clawback policy, so that when so adopted such Clawback policy will be attached as an exhibit to the Company’s Compensation Policy and form an integral part thereof, intended to comply with the clawback-related listing standards proposed by the Nasdaq Stock Market and the Israeli Companies Law 5759-1999, as amended, to take effect upon the effective date of the Nasdaq listing rule.
|
| 2024-02-29 |
详情>>
业绩披露：
2021年年报每股收益-7.25美元,归母净利润-724.6万美元,同比去年增长-78.78%
|
| 2024-02-29 |
详情>>
业绩披露：
2023年年报每股收益-7.14美元,归母净利润-934.4万美元,同比去年增长-6.28%
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-4.12美元,归母净利润-448.9万美元,同比去年增长-27.64%
|
| 2023-07-03 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2023-05-15 |
详情>>
业绩披露：
2023年一季报每股收益-0.22美元,归母净利润-230.8万美元,同比去年增长-36.25%
|
| 2023-05-04 |
股东大会：
将于2023-06-08召开股东大会
会议内容 ▼▲
- 1.To approve the re-election of Prof. Eli Hazum, Dr. Ehud Geller and Efi Cohen-Arazi, to the board of directors of the Company (the “Board of Directors”), each until the next annual general meeting of shareholders (a separate vote for each director will be taken)._x000D_
2.To approve a grant of options to Prof. Eli Hazum, Dr. Ehud Geller and Efi Cohen-Arazi, all of which are members of the Board of Directors._x000D_
3.To ratify and approve certain adjustments of the compensation terms of Ilan Hadar, the Chief Executive Officer of the Company._x000D_
4.To increase the Company’s authorized share capital by 23,333,333 shares, such that following the increase, the authorized share capital shall equal NIS 1,500,000 divided into 50,000,000 ordinary shares, par value NIS 0.03 each, and to amend the Company’s Articles of Association accordingly._x000D_
5.To approve a reverse split of the Company ordinary shares, NIS 0.03 nominal par value each, at a ratio of 1 share for 10 shares, so that each ten (10) ordinary shares of the Company, nominal value NIS 0.03 each shall be recapitalized into one (1) ordinary share of the Company, nominal value NIS 0.3 each, and to amend our Articles of Association accordingly._x000D_
6.To approve the re-appointment of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited (the “Auditors”), as the Company’s independent registered public accounting firm for the year ending December 31, 2023, and to authorize the Board of Directors, upon the recommendation of the Company’s audit committee, to determine the Auditors’ remuneration to be fixed in accordance with the volume and nature of their services to the Company for such fiscal year._x000D_
7.To review and discuss our financial statements for the year ended December 31, 2022, and to transact such other business as may properly come before the meeting.
|
| 2023-05-03 |
股东大会：
将于2023-06-01召开股东大会
会议内容 ▼▲
- 1.To approve the re-election of Prof. Eli Hazum, Dr. Ehud Geller and Efi Cohen-Arazi, to the board of directors of the Company (the “Board of Directors”), each until the next annual general meeting of shareholders (a separate vote for each director will be taken).
2.To approve a grant of options to Prof. Eli Hazum, Dr. Ehud Geller and Efi Cohen-Arazi, all of which are members of the Board of Directors.
3.To ratify and approve certain adjustments of the compensation terms of Ilan Hadar, the Chief Executive Officer of the Company.
4.To increase the Company’s authorized share capital by 23,333,333 shares, such that following the increase, the authorized share capital shall equal NIS 1,500,000 divided into 50,000,000 ordinary shares, par value NIS 0.03 each, and to amend the Company’s Articles of Association accordingly.
5.To approve a reverse split of the Company ordinary shares, NIS 0.03 nominal par value each, at a ratio of 1 share for 10 shares, so that each ten (10) ordinary shares of the Company, nominal value NIS 0.03 each shall be recapitalized into one (1) ordinary share of the Company, nominal value NIS 0.3 each, and to amend our Articles of Association accordingly.
6.To approve the re-appointment of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited (the “Auditors”), as the Company’s independent registered public accounting firm for the year ending December 31, 2023, and to authorize the Board of Directors, upon the recommendation of the Company’s audit committee, to determine the Auditors’ remuneration to be fixed in accordance with the volume and nature of their services to the Company for such fiscal year.
7.To review and discuss our financial statements for the year ended December 31, 2022, and to transact such other business as may properly come before the meeting.
|
| 2023-03-15 |
详情>>
业绩披露：
2022年年报每股收益-0.82美元,归母净利润-879.2万美元,同比去年增长-21.34%
|
| 2022-11-25 |
股东大会：
将于2022-12-29召开股东大会
会议内容 ▼▲
- 1.To approve the re-election of Prof. Eli Hazum, Dr. Ehud Geller and Efi Cohen-Arazi, to the board of directors of the Company (the “Board of Directors”), each until the next annual general meeting of shareholders (a separate vote for each director will be taken).
2.To approve the re-appointment of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited (the “Auditors”), as the Company’s independent registered public accounting firm for the year ending December 31, 2022, and to authorize the Board of Directors, upon the recommendation of the Company’s audit committee, to determine the Auditors’ remuneration to be fixed in accordance with the volume and nature of their services to the Company for such fiscal year.
3.To ratify and approve the grant of options to Ilan Hadar in his capacity as the Chief Executive Officer of the Company.
4.To review and discuss our financial statements for the year ended December 31, 2021,and to transact such other business as may properly come before the meeting.
|
| 2022-11-14 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-0.53美元,归母净利润-562.6万美元,同比去年增长-2.05%
|
| 2021-10-27 |
股东大会：
将于2021-12-09召开股东大会
会议内容 ▼▲
- 1.To re-elect Prof. Eli Hazum to the board of directors of the Company (the “Board of Directors”), for a term expiring at our next annual general meeting of shareholders.
2.To re-elect Dr. Ehud Geller to our Board of Directors for a term expiring at our next annual general meeting of shareholders.
3.To re-elect Efi Cohen-Arazi to our Board of Directors for a term expiring at our next annual general meeting of shareholders.
4.To appoint Kesselman & Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as the Company’s independent auditors for the fiscal year ending December 31, 2021, instead of Brightman Almagor Zohar & Co., Certified Public Accountants, a firm in the Deloitte Global Network, and to authorize the Board of Directors, upon the recommendation of the Company’s audit committee (the “Audit Committee”), to determine the auditors’ remuneration to be fixed in accordance with the volume and nature of their services to the Company for such fiscal year.
5.To increase our authorized share capital by NIS 3,000,000, such that following the increase, the authorized share capital shall equal NIS 8,000,000 divided into 26,666,666 ordinary shares, par value NIS 0.03 each, and to amend our articles of association accordingly.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-01-19 |
股东大会：
将于2021-02-23召开股东大会
会议内容 ▼▲
- 1.To approve the Compensation Policy of the Company.
2.To approve the employment terms of Ilan Hadar in his capacity as the Chief Executive Officer of the Company.
3.To ratify the approval of the election of Augustine Lawlor to hold office as an external director of the Company for a period of three years effective from September 1, 2020.
4.To ratify the approval of the election of Dr. Ellen S. Baron to hold office as an external director of the Company for a period of three years effective from September 1, 2020.
5.To ratify and approve the compensation terms of the non-executive directors of the Company (Augustine Lawlor, Dr. Ellen S. Baron and Effi Cohen Arazi).
6.To ratify and approve the grant of options to all serving directors of the Company.
|